Wall Street brokerages expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to report sales of $280,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from $250,000.00 to $300,000.00. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 29th.
According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full year sales of $1.57 million for the current year, with estimates ranging from $1.50 million to $1.60 million. For the next year, analysts forecast that the firm will report sales of $440,000.00, with estimates ranging from $400,000.00 to $500,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, August 30th. The company reported ($2.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($2.12). The business had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.09 million.
CRNX has been the subject of several analyst reports. Piper Jaffray Companies initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued an “overweight” rating and a $40.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued a “neutral” rating and a $29.00 target price for the company. Leerink Swann initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $43.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, October 15th.
CRNX traded down $0.53 during trading on Wednesday, hitting $22.87. 239,175 shares of the company’s stock were exchanged, compared to its average volume of 106,787. Crinetics Pharmaceuticals has a fifty-two week low of $19.23 and a fifty-two week high of $42.00.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Read More: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.